Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration (Q34396862)

1 August 2017

Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration (English)

1 reference

1 August 2017

5

Edward Wylegala

1 reference

1 August 2017

Slawomir J Teper

1

1 reference

1 August 2017

Anna Nowinska

series ordinal

2

1 reference

1 August 2017

Jaroslaw Pilat

series ordinal

3

1 reference

1 August 2017

Andrzej Palucha

series ordinal

4

1 reference

1 August 2017

7 December 2010

1 reference

1 August 2017

1 reference

1 August 2017

16

1 reference

1 August 2017

2598-2604

1 reference

The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a long-term study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Ranibizumab for neovascular age-related macular degeneration

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000236

Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21151600

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21151600

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

PMCID

3000236

1 reference

1 August 2017

1 reference